How proteogenomics can improve drug discovery and development
- Drug discovery & development , Proteogenomics
- Read time: 7 minutes
With the advancement of available technologies in recent years, researchers are fast becoming aware of the advantages of using proteomics in their research to better understand human biology and disease and to drive pharmaceutical development towards new and improved therapies.
Dr. Anders Mälarstig, Director of human genetics at Pfizer, came to this realization early on. While he began his research career using genetics to understand cardiovascular disease, he soon turned to proteomics, and specifically protein quantitative trait loci (pQTLs) to take his research one step further.
In the following interview, Dr. Mälarstig makes the case for this proteogenomics approach to advance basic and clinical research and speaks to its advantages in the drug discovery and development space.
pQTLs are at the heart of the success of the proteogenomics approach
Protein quantitative trait loci are gene variants that are associated in some way with circulating protein levels. Therefore, they give much information on how genes regulate proteins. As proteins are the targets for most current drugs, pQTLs serve as models of pharmaceutical intervention, which is important for drug development.
By mapping all the pQTLs for proteins circulating in our blood, we then have pharmaceutical models for an array of biological processes, which pharmaceutical researchers can directly interrogate to identify new, robust drug targets.
Crucially, the identification of pQTLs within the genes responsible for the affected proteins (“cis-pQTLs”), combined with Mendelian Randomization from phenotypic data, provides the strongest possible evidence that a given protein is causal in the disease being studied.
In basic research, pQTLs may be used to discover other genes that regulate protein levels and may thus be used to map new biological pathways without having to do specific cultivation experiments in cells and animals. In this way, what would have taken multiple hours of research and numerous experiments to achieve may be accomplished with a relatively simple experiment.
How proteogenomics benefits the drug discovery industry
Proteogenomics may not only be used to identify promising drug targets more efficiently but are also useful in stratifying patients in clinical trials and identifying which patients will respond favorably to interventions targeting biological pathways.
Dr. Mälarstig gives an example from their recently published paper in Nature Metabolism, whereby they used soluble ST2 levels to stratify patients into high and low soluble ST2 expression, which would affect how favorably patients would respond to therapy targeting soluble ST2.
As the science continues to develop, more and more companies are incorporating proteogenomics and proteomics into their repertoire of research approaches. Most recently, UK Biobank selected Olink as their proteomics partner for a large-scale collaborative project funded by a consortium of leading biopharmaceutical companies to identify pQTLs in a subset of their sample bank. You can read more on this initiative here.
The science is still in its infancy, but as pharmaceutical companies like Pfizer continue to drive research combining proteomics and genomics, it is only a matter of time until a significant proportion of pharma company pipelines will be developed from protein biomarkers. Pfizer is now expanding its research from blood to cerebral spinal fluid to investigate diseases like dementia and is following up on leads generated from proteogenomics approaches with functional genomics and traditional cell biology.
Olink’s technology makes it easy to implement the proteogenomics approach into your research
In the early days of his proteogenomics research efforts, Dr. Mälarstig approached Olink to help him with a pQTL study. Despite the study using a small sample size, the proteomics results were of such high quality that the study authors were able to already detect genes encoding their proteins of interest. In contrast, a normal genome-wide association study requires the investigation of some 15 million variants to achieve the same results.
The future is bright with the medical advances to be made using proteogenomics, and we are only just beginning to glean the benefits of this approach.
The success of this early research eventually led to Dr. Mälarstig developing the SCALLOP consortium in 2017. This collaborative framework is set up to share data between researchers who have both genomic and Olink-derived protein data and wish to increase the power of their studies by combining results from those of other investigators. Currently, the SCALLOP consortium has 28 PIs making up its ranks, with Olink proteomics and genomics data from over 40 different human cohort studies.
According to Anders Mälarstig, the future is bright with the medical advances to be made using proteogenomics, and we are only just beginning to glean the benefits of this approach.
How the proteome behaves in healthy individuals
Clinical research, Multiomics
To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations.
Key proteomics publications from 2020
Proteomics
Welcome to the first post of the all-new weekly Olink to Science! Our customer survey revealed that you would like to know more about the many publications, research, and other science happening at Olink, therefore this blog aims to do just that: keep you informed on the exciting science taking place with our technology.
Protein biomarkers are crucial in early detection of cancer
Clinical research, Oncology, Protein biomarkers
A central premise of precision medicine is to identify biomarkers indicative of disease transitions early on. This is especially important in cancer where early treatment intervention could increase a patient’s chance of survival and reduce the probability of cancer recurrence.
Using PEA and RNA-Seq to study disease pathology
Clinical research, Proteomics
The following study illustrates how transcriptomics and proteomics complement one another to clarify the pathology of a complex, and little understood disease. Atopic dermatitis (AD) is the most common chronic skin condition affecting up to 20% of children and 7-10% of adults, depending on the population.
Olink protein biomarker panel indicates fermented foods fight inflammation
Inflammation, Proteomics
Could food be used to fight chronic disease?
Study identifies proteins involved in immunotherapy response
Oncology, Proteomics
'Ultimately, it is all about understanding and treating patients better in the future.'
Proteins diagnostic of lung cancer up to 5 years before disease onset
Oncology
An earlier Olink to Science blog post covered some amazing research that found that certain blood protein biomarkers have the potential to predict cancer up to 3 years before diagnosis. This may also be the case for lung cancer, as detailed in a recent study by Dagnino and her colleagues, where elevated levels of CDCP1 were detected in participants of a cohort who later developed the disease.
Utilizing proteogenomics technology for novel drug target discovery
Drug discovery & development
High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation.
Developing a high-performance biomarker panel for Alzheimer’s disease
Clinical research, Neurology, Protein biomarkers
A simple search of the term ‘scourge of Alzheimer’s Disease’ brings up over half a million website hits. A major disease, about 15% of us that reach the age of 67 to 74, and 44% of those 75 to 84 will develop AD.
How proteomics helped diabetic kidney disease research advance
Clinical research, Proteomics
Dr. Krolewski and his team at the Harvard Medical School found 56 proteins to be significant in diabetic kidney disease patients. Potentially, these could serve as prognostic biomarkers for disease progression and treatment response. This is how adding proteomics to the methodologies elevated their research.
2947
Biomarker assays
~881 million
Protein data points generated
1182
Publications listed on website